Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 54 clinical trials
Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study

pertuzumab (PTC-Ptz) in stage II-Ill HER2-positive breast cancer.

her2/neu-positive breast cancer
erbb2
immunostimulant
herceptin
adjuvant therapy
  • 19 views
  • 24 Jan, 2021
  • 52 locations
Detect V / CHEVENDO (Chemo vs. Endo)

Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin (trastuzumab) and Perjeta (pertuzumab) plus Kisqali (ribociclib) in patients with HER2 positive and

eribulin
platelet count
capecitabine
herceptin
measurable disease
  • 27 views
  • 23 Jan, 2021
  • 1 location
Testing the Addition of an Anti-cancer Drug Copanlisib to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

This phase Ib/II trial studies the side effects and best dose of copanlisib when given together with trastuzumab and pertuzumab and to see how well they work after induction treatment in

targeted therapy
stage iv breast cancer
tumor cells
hormone therapy
PTEN
  • 0 views
  • 02 Mar, 2021
  • 1 location
Concurrent WOKVAC Vaccination Chemotherapy and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab

  • 0 views
  • 03 Feb, 2021
  • 1 location
Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer

This study is to explore the markers in early prediction of the efficacy of pre-operative pertuzumab plus trastuzumab (PH) combined with chemotherapy for early stage or locally advanced human

her-2
growth factor
cancer
pertuzumab
primary tumor
  • 0 views
  • 25 Jan, 2021
  • 1 location
A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging

treatment with anthracycline and/or trastuzumab and pertuzumab-based chemotherapies, which are known to cause cardiac toxicities. Breast cancer patients will undergo a "cardio-oncology echocardiogram" which

diabetes
tumor marker
heart failure
cancer
pertuzumab
  • 25 views
  • 23 Jan, 2021
  • 1 location
TPIV100 and Sargramostim for the Treatment of HER2 Positive Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is a type of vaccine made from HER2 peptide that may help the

international normalized ratio
staining intensity
tumor cells
platelet count
placebo administration
  • 0 views
  • 24 Jan, 2021
  • 3 locations
Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy

achieving a complete response following standard anti-HER2-based neoadjuvant therapy with paclitaxel/trastuzumab/pertuzumab. The primary trial objective is to estimate the loco-regional invasive disease

  • 0 views
  • 25 Jan, 2021
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+ HER2+ Advanced Breast Cancer Patients

including trastuzumab and pertuzumab (THP) is considered as standard of therapy based upon randomized phase 3 clinical trial (CLEOTATRA). HER2 positive breast cancer can be divided into HER2 enriched

chromogenic in situ hybridization
stage iv breast cancer
palbociclib
ejection fraction
breast cancer
  • 0 views
  • 26 Jan, 2021
  • 1 location
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

The study assesses the efficacy of neoadjuvant treatment with pyrotinib and trastuzumab with chemotherapy, mainly pathological complete response (pCR) rates in the breast and axilla. And also assesses side effects, event-free survival (EFS), disease-free survival (DFS), distant disease-free survival (DDFS), and objective response rates (ORR).

  • 0 views
  • 02 Feb, 2021
  • 1 location